The xanthine oxidase inhibitor oxypurinol does not limit infarct size in a canine model of 40 minutes of ischemia with reperfusion. 1988

J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710.

Free radicals such as superoxide (.O2-) produced by xanthine oxidase might cause cell death during reperfusion after myocardial ischemia. The effect of the xanthine oxidase inhibitor allopurinol on infarct size in ischemia-reperfusion models has been variable, possibly because of differences in treatment duration. Adequate inhibition of xanthine oxidase may require a sufficient pretreatment period to permit conversion of allopurinol to oxypurinol, the actual inhibitor of superoxide production. To test more definitively whether xanthine oxidase-derived free radicals cause cell death during reperfusion, the effect of oxypurinol on infarct size was evaluated in an ischemia-reperfusion model. Open chest dogs underwent 40 min of circumflex coronary artery occlusion followed by reperfusion for 4 days. Twelve dogs were treated with oxypurinol (10 mg/kg body weight intravenously 10 min before occlusion and 10 mg/kg intravenously 10 min before reperfusion) and 11 control dogs received drug vehicle alone (pH 10 normal saline solution). Nine control dogs from a concurrent study also were included. Infarct size was measured histologically and analyzed with respect to its major baseline predictors, including anatomic area at risk and collateral blood flow (measured with radioactive microspheres). Infarct size as a percent of the area at risk averaged 23.8 +/- 2.7% (mean +/- SEM) in the oxypurinol group (n = 10) and 23.1 +/- 4.2% in the control group (n = 17) (p = NS). Collateral blood flow to the inner two thirds of the ischemic wall averaged 0.08 +/- 0.01 ml/min per g in the oxypurinol group and 0.09 +/- 0.02 ml/min per g in the control group.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010117 Oxypurinol A xanthine oxidase inhibitor. Alloxanthine,Oxipurinol
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
March 1991, Circulation,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
May 1985, Circulation,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
November 1990, Clinical and experimental pharmacology & physiology,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
September 1987, Circulation,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
June 2010, Journal of cardiovascular pharmacology and therapeutics,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
April 1990, Circulation,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
April 1990, The Journal of pharmacology and experimental therapeutics,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
December 1991, American heart journal,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
December 2017, Cardiovascular drugs and therapy,
J M Kinsman, and C E Murry, and V J Richard, and R B Jennings, and K A Reimer
June 1988, American heart journal,
Copied contents to your clipboard!